Cellphire Therapeutics gets FDA Fast Track for CLPH-511
Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...
PEP-Therapy’s lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment...
Radiopharm Theranostics presented data at EMIM 2025 demonstrating the effectiveness of RAD202, a HER2-targeting single domain antibody, for both...
Bitterroot Bio will present Phase 1 study results for BRB-002, a novel anti-CD47 therapy for atherosclerotic cardiovascular disease (ASCVD),...
Curevo Vaccine secured $110 million in Series B funding to advance the development of its shingles vaccine, amezosvatein. The...
NurExone Biologic Inc. has successfully completed a preclinical study of its ExoPTEN treatment for spinal cord injuries, demonstrating significant...
Gradalis, a clinical-stage biotech company, published a peer-reviewed article in Scientific Reports detailing their novel exome sequencing procedure and...
Korro Bio announced that its investigational medicine, KRRO-110, received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin...
Gain Therapeutics has dosed the first Parkinson’s disease patient in a Phase 1b clinical trial of its lead candidate,...
Eton Pharmaceuticals announced positive results from a bioequivalence study of ET-600, its patented oral solution of desmopressin for central...